Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098646 | 0.87 | HTT (0.60) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL29800437 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL3071086 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL11240386 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL5188245 | 0.85 | TDP1 (0.61) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL23833731 | 0.85 | TDP1 (0.57) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL14451779 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL29451712 | 0.83 | ALDH1A1 (0.66) | SMN1; SMN2TDP1HTTLMNAALDH1A1 | |
| SCHEMBL2646997 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2TDP1HTTALDH1A1L3MBTL1 | |
| SCHEMBL11322982 | 0.81 | TDP1 (0.53) | SMN1; SMN2TDP1HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| CN-112996496-A | substituted-3H-imidazo [4,5-c ] pyridines and 1H-pyrrolo [2,3-c ] pyridines as novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and interferon gene Stimulator (STING) modulators for cancer immunotherapy | 斯汀格瑞治疗股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3829561-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2020-02-06 | — | — | US | disclosed |
| WO-2020028724-A1 | SUBSTITUTED-3H-IMIDAZO[4,5-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATORS AS CANCER IMMUNOTHERAPEUTICS | Stingray Therapeutics, Inc. (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039979-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | SMN1; SMN2 3292/4885TDP1 55/4885HTT 4506/4885 |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | SMN1; SMN2 3957/4885TDP1 606/4885HTT 4634/4885 |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | SMN1; SMN2 3292/4885TDP1 55/4885HTT 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.